Covid-19: Where We Go From Here

August 18, 2020

AI Summary

5 min read

In July 2020, a world leader asked Harvard epidemiologist Dr. Mark Lipsitch a surprisingly naive question: don’t viruses eventually run out of ink, like a copier cartridge? Lipsitch’s answer was blunt. “Viruses just don’t run out of ink. There’s no natural limit on viral spread other than immune people blocking chains of transmission or deliberate efforts to block chains of transmission.” That exchange captures the central tension of the pandemic’s next phase: without herd immunity or effective controls, the virus will keep finding susceptible hosts. This episode of Top of Mind at Goldman Sachs assembles three expert perspectives—an epidemiologist, a chief economist, and a vaccine developer—to assess where the virus, the economy, and the vaccine pipeline stand, and what realistic timelines look like for a return to something like normal.

The Three Levers That Determine Viral Spread

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of Top of Mind at Goldman Sachs

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (00:57) **Dr. Mark Lipsich on Where the Pandemic Stands** - The Harvard epidemiologist explains why the virus is far from burned out.
2 (03:39) **Three Factors That Determine the Virus's Path** - Lipsich identifies the multipliers on the reproduction number: herd immunity, seasonality, and control measures.
3 (05:56) **Why Past Outbreaks Create Caution, Not Just Immunity** - Lipsich observes that populations that experienced a severe wave become more cautious, a "companion notion to herd immunity."
4 (07:51) **Best-Case Resolution Timeline: Mid-2021** - Lipsich says 2021 as the resolution year is the best-case scenario, but we won't know until at least the middle of next year.
5 (10:07) **Jan Hatzius on the Halfway Recovery** - The chief economist assesses the global economy as about halfway through the recovery from the corona crisis.
6 (12:01) **Low-Cost Measures vs. Lockdowns** - Hatzius explains how face mask mandates can substitute for economically damaging broad lockdowns.
7 (15:25) **The Vaccine Timeline and Its Economic Impact** - The economists assume FDA approval of at least one vaccine before year-end, with vaccination of most US/European populations by late 2021.

+ Full timestamped outline available in the app

Show Notes

Well into the COVID-19 pandemic, countries continue to grapple with managing the virus while restoring economic activity. Where the virus will go from here, what that means for the economy and markets—and how the vaccine outlook might impact everything—is Top of Mind.

In this episode, Allison Nathan speaks to Harvard’s Dr. Marc Lipsitch, who believes that the rising expectation for a resolution of the pandemic in 2021 is a plausible best-case scenario, but one we likely won’t be sure of until at least midyear. Our own Jan Hatzius argues that economic activity should be able to normalize further even if the virus remains an issue, and that a vaccine would only reinforce the economic recovery. Finally, Allison asks CEPI CEO, Dr. Richard Hatchett, if the rise in vaccine optimism is warranted. He’s also hopeful about the vaccine timeline, but cautions vaccines likely won’t be a magic bullet.